Introduction The Lausanne University Hospital, also known as Centre Hospitalier Universitaire Vaudois, is a private company in Switzerland that operates university hospitals. With its 16 clinical and medico-technical departments and numerous services, the hospital is renowned for its academic achievements in healthcare, research, and teaching. It collaborates with the Faculty of Biology and Medicine of the University of Lausanne and the Swiss Federal Institute of Technology in Lausanne (EPFL) to establish itself as a center of medical education and research. |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 1 |
Diagnostic radiopharmaceuticals | 1 |
Antisense oligonucleotides | 1 |
Unknown | 1 |
Oligonucleotide | 1 |
Target |
Mechanism TLR9 agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Mechanism HIV envelope protein gp120 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism αvβ3 antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Dec 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator [+5] |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
[68Ga]NODAGA-RGD ( αvβ3 ) | Plaque, Atherosclerotic More | Phase 2 Clinical |
Vidutolimod ( TLR9 ) | Triple Negative Breast Cancer More | Phase 2 |
HTX-001 | Cardiomyopathy, Hypertrophic More | Preclinical |
AER-003 ( SARS-CoV-2 S protein ) | COVID-19 More | Preclinical |
Long Non-Coding RNA inhibitors(HAYA Therapeutics SA/Centre Hospitalier Universitaire Vaudois) ( RNA ) | Squamous Cell Neoplasms More | Discovery |